Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies

Off-target toxicity due to the expression of target antigens in normal tissue represents a major obstacle to the use of chimeric antigen receptor (CAR)-engineered T cells for treatment of solid malignancies. To circumvent this issue, we established a clinical platform for engineering T cells with tr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Beatty, Gregory L., Haas, Andrew R., Maus, Marcela V., Torigian, Drew A., Soulen, Michael C., Plesa, Gabriela, Chew, Anne, Zhao, Yangbing, Levine, Bruce L., Albelda, Steven M., Kalos, Michael, June, Carl H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3932715/
https://ncbi.nlm.nih.gov/pubmed/24579088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-13-0170
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak